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Abstract Treatment of psoriasis with vitamin D3 ana­
logues is well established in present dermatological 
practice. One of the clinical signs of the psoriatic 
plaque that reduces early and markedly during treat­
ment with the vitamin D3 analogue calcipotriol is scal­
ing. Since scaling is the clinical manifestation of disor­
dered epidermal differentiation, early changes in im- 
lmmohistochemical markers for differentiation (trans­
glutaminase, involucrin and filaggrin) were studied in 
patients who had been treated with calcipotriol for 4 
weeks. Markers for proliferation (Ki-67 antigen) and 
inflammation (polymorphonuclear leucocytes and T 
lymphocytes) were also studied and correlated with 
the differentiation characteristics. Clinically, a major 
improvement was seen in all patients. A significant de­
crease in the percentage of transglutaminase-positive 
cell layers was observed during the first week of treat­
ment. In contrast, an increase in transglutaminase ac­
tivity in epidermal cell cultures following incubation 
with calcipotriol has been reported. Involucrin expres­
sion was only slightly modulated in vivo. However, a 
major restoration of the filaggrin-positive cell layer 
and significant reduction in the recruitment of cycling 
epidermal cells characterized the epidermal response 
to calcipotriol treatment. Markers for inflammation 
(Til-positive cells and elastase-positive cells) were also 
reduced substantially during the first week of treat­
ment with calcipotriol. From this study it may be con­
cluded that inhibition of epidermal growth and recov­
ery of the filaggrin-positive cell layer are among the in 
vivo effects of calcipotriol.
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Vitamin D3 and its analogues have been shown to exert an 
important antipsoriatic effect [1]. In vitro and in vivo 
studies have shown a marked antiproliferative and kera- 
tinization-enhancing activity [2-6]. Inflammation is also 
affected by active vitamin D3 derivatives [6, 7].
Calcipotriol is one of the first line treatments for psori­
asis. While treating patients with this therapy, it is our im­
pression that scaling is one of the clinical signs that d i­
minishes early and obviously. So one might speculate that 
normalization of epidermal differentiation is one of the 
important antipsoriatic effects of active vitamin D3. In­
deed, in vitro studies have shown that proliferation of ker- 
atinocytes is inhibited and that the formation of the corni- 
fied envelope, transcription of involucrin and transgluta­
minase activity are enhanced by calcipotriol [2, 3, 7—12J. 
In vivo, inhibition of Ki-67 expression and a reduction in 
polymorphonuclear leucocytes (PMN) are early effects, 
whereas a reduction in suprabasal expression of keratin 16 
and T lymphocyte accumulation are late effects [6|.
The aim of the present study was to elucidate the be­
haviour of the suprabasal compartment of the epidermis 
during treatment of psoriatic plaques with calcipotriol 
The following questions were addressed;
(1) Does calcipotriol ointment have a substantial effect on 
markers of epidermal differentiation during the treatment 
of chronic plaque psoriasis?
(2) What is the relationship between the effect on differ­
entiation markers and other immunohistochemical effects 
of calcipotriol?
A 4-week clinical study with calcipotriol in patients with 
psoriasis was carried out to answer these questions. Cryo­
stat sections of skin biopsies were studied immunohisto- 
chemically using a panel of monoclonal antibodies.
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Materials and methods
Patients
Six patients with chronic plaque psoriasis, five males and one fe­
male, participated in this study. Their ages ranged from 33 to 61 
years and their average duration of psoriasis was 17 ± 0,8 (mean ± 
SEM) years. They had used no systemic treatment for at least 2 
months and no topical treatment for at least 2 weeks. In fact, the 
patients had hardly used any antipsoriatic treatment for periods of 
months or years before starting the present study. Patients were in­
structed to apply calcipotriol ointment (50 jig/g; Daivonex, LEO 
Pharma, Denmark) twice daily to lesionai skin with a maximum of 
100 g ointment weekly. No additional topical therapy was allowed. 
This study was approved by the local ethical committee. AI! pa­
tients gave their written informed consent prior' to inclusion in the
munoglobulin conjugated with peroxidase (1:50, RAM-PO; 
Dakopatts) diluted in PB containing 5% human ÁB serum for 30 
min. After washing with PB and demineralized water, staining was 
visualized using a 3-amino-9-ethylcarbazo.le (AEC) solution.
Staining with T i l  was done with an indirect peroxidase-an- 
tiperoxidase technique (PAP). The slides were put in PB for 10 
min and preincubated with 50% normal rabbit serum in PB for 20 
min. After washing with PB the slides were incubated with the pri­
mary monoclonal antibody in a Miele Microwave at 80 W for 9 
min. The slides were then washed again in PB and incubated with 
rabbit antimouse immunoglobulin (1:25, RAM-Ig; Dakopatts) in 
the microwave at 80 W for 9 min. After washing in PB the slides 
were incubated with PAP complexes (I: 100, peroxidase mono­
clonal mouse antiperoxidase complexes; Dakopatts) in the mi­
crowave at 80 W for 8 min. After washing, this cycle was repeated. 
The complexes were visualized using the AEC solution.
All slides were counters tai ned with Mayer's haeniatoxylin 
(Sigma, SL Louis, Mo.f USA) and mounted in glyeerol-gelatine.
Clinical assessments Misto logica l examìnalio n
efore therapy and 1, 2 and 4 weeks after therapy the severity of 
one target lesion was scored for each of the following clinical 
signs: erythema, induration and scaling. Each parameter was 
scored using a 5-point scale: 0 = complete lack of cutaneous in­
volvement, I = slight involvement, 2 = moderate involvement, 3 = 
severe involvement, 4 = severest possible involvement.
Biopsy procedure
Punch biopsies of 3 mm were taken from the previously deter­
mined target lesion before therapy and 1, 2 and 4 weeks after ther­
apy from all patients after local anaesthesia with 1% Xylocaine 
and adrenaline. The biopsies were embedded in Tissue Tek OCT 
compound (Miles, Scientific, Naperville, Ul., USA), snap frozen in 
liquid nitrogen and stored at -80° C until use. Sections of 7 |um 
were cut, air dried and fixed for 10 min in acetone/ether (60/40%) 
(MlB-1 staining) or in acetone (other staining«) and again stored at 
-80° C.
The histological examination was performed blinded. Epidermal 
proliferation was measured by counting the number of MlB-1 -pos­
itive nuclei per millimetre length of section. Involucrin and trans­
glutaminase expression were assessed by calculai ion of the ratio of 
positive cell layers to total cell layers of the viable epidermis. This 
was done at two sites: above the dermal papilla and between two 
dermal papillae, Filaggrin expression was assessed by measuring 
the percentage of the length of the stratum corneum and stratum 
granulosum which was stained.
Inflammation (PMN and T lymphocytes) was assessed sepa­
rately for the dermis and epidermis. Dermal inflammation was 
semiquantitatively evaluated by expressing the number of posi­
tively stained cells as a percentage of the total number of infiltrate 
cells [14]; 0, no positive cells; I, sporadic positive cells; 2, 1-25%;
3, 26-50%; 4, 51-75%; 5, 76-99%; 6, 100%. Epidermal inflam­
mation was assessed using a five-point scale: 0» no staining; 1, 
sporadic staining; 2, minimal staining; 3, moderate staining; 4, 
pronounced staining.
M onoc Ion a I an t i bod ies
A panel of monoclonal antibodies was used. To assess epidermal 
differentiation monoclonal antibodies against involucrin (MON- 
150 [13J, I :25), antihuman keratinocyte transglutaminase (1:25, 
Mouse Monoclonal Antibody, IgG^; BT621; Biomedical Technolo­
gies, Stoughton, Mass., USA) and against filaggrin and profilag- 
grin (I :500, antifilaggrin, BT576; Biomedical Technologies) were 
used. To estimate the number of cycling epidermal cells in the 
basal layer an antibody directed against the Ki-67 antigen was used 
(MIB-1, I :50; Immunoleeh, Marseilles, France).
The inflammatory infiltrate was analysed by assessing Ihe T 
lymphocytes and PMN using, respectively, the monoclonal anti­
bodies DAKO-T11 (1:100; Dakopatts, Copenhagen, Denmark) 
and DAKO-elastase (1 : 100; Dakopatts).
Staining procedure
For all monoclonal antibodies, except T i l ,  an indirect im- 
munoperoxidase technique was used. For 10 min the .slides were 
fixed in acetone/ether (60/40%) in the ease of MIB-l or in acetone 
for the other stainings. The slides were air dried and put in a phos­
phate buffer (PB; 72 mM Na2H P 04 and 28 mAf NaH2PO(I). Only 
the slides stained with antielastase were prei neu bated with 
mcthanol/0.1 % H20 2 (30%) for 20 min. All antibodies were di­
luted in PB, The slides were incubated with the different primary 
monoclonal antibodies for 30 min except for the antibody against 
transglutaminase (60 min). After washing with PB the slides were 
incubated with the secondary antibody, rabbit anlhnouse im-
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Fig. 1. Erythema (— ), induration (------) and scaling (—  -) be­
fore and during t rca I meni with calcipotriol expressed as means ± 
SEM
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Fig.2a-c a Transglutaminase above ihe dermal papilla before 
and during treatment with calcipotriol; b transglutaminase be­
tween two dermal papillae before and during treatment with cal­
cipotriol; c Involucrin above the dermal papilla before and tim­
ing treatment with calcipotriol; d Involucrin between two der­
mal papillae before and during treatment with calcipotriol; c fi-
iaggrin in the stratum corneum (------ ) and stratum granulos uni
(------ ) before and during treatment with calcipotriol, Values are
means ± SEM. The shaded areas (a-d) represent the mean ± 2 x 
SD of the value for normal skin [ 15, 33]
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For statistical analysis the Mest lor paired values was used. A two- 
tailed hypothesis was employed to interpret the data.
Results
Clinical response
The course of the clinical scores of the target lesions is 
shown in Fig. 1.
Transglutaminase expression (Fig. 2 a) above the dermal 
papilla showed a significant decrease during the first 
week of therapy (P = 0.03), but during subsequent weeks 
no significant changes were seen, in the interpapillary 
epidermis transglutaminase expression (Fig. 2 b) slightly 
diminished resulting in a significant difference alter 4 
weeks of therapy (P = 0 .0 1). After 4 weeks of  therapy 
normal values were reached [15], Involucrin expression
crease (P = 0.04) after 4 weeks of therapy, but involucrin
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Fig.3 Anlifilaggrin staining in the same patient before (a) and ai 
ter (b) 4 weeks of therapy
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Fig.4 M Iß -1 staining before and during treatment with cal­
ci potriol expressed as means ± SEM (the shaded area represents 
the mean ± 2 x  SD of the value for normal human skin [16])
expression in the interpapillary epidermis (F ig.2d) did 
not show significant changes. Filaggrin staining (Fig.2e) 
in the stratum corneum significantly increased after 2
= 0.04). In the stratum granulosum a significant 
increase was seen as early as after I week of treatment (P = 
0.01). Recovery of the stratum corneum was only partial, 
but recovery of the stratum granulosum was nearly com­
plete. Immunohistochemical staining for filaggrin before 
and after therapy is shown in Fig. 3.
The number of Ki-67-positive nuclei per millimetre of 
section (Fig. 4) significantly decreased during the first 
week of therapy (P 
no significant changes were seen. The number of Ki-67- 
positive nuclei approached, but remained above, the nor­
mal range 116 ].
The staining of T lymphocytes in the dermis (Fig. 5 a) 
altered significantly after the first week of therapy (P = 
0.003), but subsequently no significant changes, were ob­
served. T i l  staining in the epidermis (Fig.5b) showed a
to decrease (P = 0.08) during the first week, but 
during subsequent weeks no significant changes were 
seen. Antielastase staining (PMN) in
= 0.01 ), but no further significant changes were observed. 
In the epidermis no changes in eliistase binding were ob­
served. Epidermal T lymphocyte accumulation and PMN 
accumulation remained above the range for normal skin
Discussion
In the present study, a major clinical i 
observed during a 4-week treatment
as
with cal­
cale ipotriol treatment since the reduction in
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Fig,5 a—c a, b T1I positivity before and during treatment with 
calcipotriol. a Dermis (the shaded area represents the mean ± 2 x  
SD of the value for normal human skin [15]); b epidermis, c
AntieJastase in the dermis (------ ) and epidermis (------ ) before and
during treatment with calcipotriol, Values are means ± SEM
severity scores is reached after an 8-week treatment pe­
riod [17]. Most studies agree that calcipotriol induces pro­
nounced changes in epidermal behaviour, leaving the 
mononuclear infiltrate relatively unaffected [6, 18-20], 
The present results are in line with these studies and clin­
ically, an early and relatively pronounced effect of cal­
cipotriol on scaling, the clinical manifestation of epider­
mal differentiation, was found.
Epidermal differentiation involves the formation of 
cornified envelopes by crosslinking (formation of the e- 
(y-glutamyl)lysine bonds) involucrin, ioricrin and kera-
tolinin involving the calcium-dependent enzyme mem- 
brane-bound transglutaminase (TGase 1) [21-24]. In nor­
mal skin, staining with antibodies against TGase 1 and in­
volucrin shows a band-like pattern in the upper part of the 
epidermis representing the upper stratum spinosum and 
the stratum granulosum [25]. In situ hybridization tech­
niques have demonstrated involucrin and TGase 1 mRNA 
at the transition to the stratum granulosum as a very early 
event in differentiation [26]. Activity of TGase 1 has been 
demonstrated in vivo in mice in the transition zone (one or 
at most two cell layers) from the stratum granulosum to 
the stratum corneum [25]. At this point the actual forma­
tion of the cornified envelopes takes place resulting in the 
stratum corneum in which antigenicity of involucrin is lost
4 [25]. In psoriatic skin, the keratinization process is dis­
turbed. Large, clinically visible, histologically parakera- 
totic squames are formed in lesionai skin [26]. Staining 
with monoclonal antibodies against involucrin and TGase 
1 demonstrates far more positive cell layers, relatively as 
well as absolutely [27]. The activity of TGase 1 and the 
number of cornified envelopes produced are also greatly 
enhanced [28]. Messenger RNA of involucrin and TGase 1 
is localized early in the lower cell layers of the suprabasal 
epidermis [26]. This is in contrast to the situation found in 
nomi al skin [26]. Increased expression of TGase 1 protein 
and mRNA in psoriasis may partly explain the characteris­
tic hyperkeratosis. The formation of a more highly 
crosslinked stratum corneum may lead to a greater reten­
tion of the squames observed in lesionai skin [29].
The present in vivo observations on epidermal differ­
entiation during treatment with calcipotriol indicate that 
modulation of the process of keratinization is a relatively 
early effect of this compound. However, these observa­
tions are in several respects at variance with in vitro ob­
servations, TGase 1 activity in cultured keratinocytes is 
enhanced by calcipotriol [2]. In the present in vivo study, 
however, TGase 1-positive cells decreased during treat­
ment. In vivo, a similar decrease has been observed dur­
ing treatment of psoriatic plaques with the vitamin D* 
analogues l,25-(OH)2-D3 and l,24-(OH)2~D3 
Whereas vitamin D3 analogues in vitro enhance the tran­
scription of involucrin [ I I, 12], only a minor modulation 
of the number of invoiucrin-positive cell layers was ob­
served in the present in vivo study. Treatment with 1,25- 
(OH)2-D:î and l,24-(OH)2-D3 reduces the number of in- 
volucrin-positive cell layers [4, 5 |. Despite the decrease in 
anti-TGase 1 binding, TGase 1 as well as involucrin re­
mained high during this investigation. The newly formed 
keratinocytes in psoriatic lesions keep on expressing 
TGase 1 and involucrin mRNA too early in their matura­
tion process. So far, there is no convincing evidence that 
calcipotriol modulates epidermal differentiation in vivo 
via DNA transcription of involucrin or TGase 1.
A remarkable and consistent effect of calcipotriol (pre­
sent study) and of l,25-(OH)2-D3 and l,24-(OH)2-D3 [4, 
5] is the pronounced reformation of the filaggrin-positive 
cell layer. Filaggrin plays a major role in the aggregation 
of keratin filaments, which results in the keratin configu­
ration as can be seen in the lower stratum corneum [30].
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The present study demonstrates a potent reduction in 
the recruitment of cycling epidermal cells (Ki-67-positive 
nuclei). This result confirms the antiproliferative activity 
as observed in earlier studies [6, 18]. The expression of 
keratin 16 and keratin 17 in the suprabasal compartment is 
considered to be related to epidermal recovery. During 
treatment with calcipotriol these hyperproliferation-asso­
ciated keratins reduce [6, 18, 31]. The antiproliferative ac­
tion of calcipotriol has proved to be consistent in the vitro 
and the in vivo situation.
Vitamin D3 analogues interfere with several elements 
of cutaneous inflammation [32]. Modification of T-cell 
subpopulations and cytokine pattern and a reduction in 
PMN accumulation have been observed previously [32]. 
The results of the present study are at variance with those 
of a previous study [6] with respect to T lymphocytes. In 
the present study the early reduction in the number of T 
lymphocytes together with the reduction in PMN accumu­
lation might be the result of the long periods (months or 
even years) that patients had been untreated. In the previ­
ous study [6], which showed only a modest effect on T 
lymphocytes, the patients had already been treated with 
calcipotriol or topical steroids up to 2 weeks before treat­
ment.
From this study it may be concluded that the in vivo ef­
fects of calcipotriol on epidermal differentiation include 
inhibition of epidermal growth, recovery of the filaggrin- 
positive cell layer and a decrease in TGase 1- and invoiu­
crin-positive cells.
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